Grand Pharmaceutical Group Ltd. Obtains Class A "Radiation Safety License" for Nuclear Medicine R&D Base, Operations to Start in June

Reuters

2025/05/18

Grand Pharmaceutical Group Ltd. Obtains Class A "Radiation Safety License" for Nuclear Medicine R&D Base, Operations to Start in June

Grand Pharmaceutical Group Limited has announced that its nuclear medicine R&D and production base in Wenjiang District, Chengdu, has secured a Class A "Radiation Safety License" from the Ministry of Ecology and Environment of China. This significant regulatory approval will allow the facility to commence operations in June. The base, which began construction in late 2022, has achieved rapid development milestones, breaking industry construction records. This facility is integral to Grand Pharmaceutical's strategic expansion in the fields of R&D, production, and sales of advanced anti-tumor technologies. The Group collaborates with organizations such as Sirtex Medical Pty Limited and Telix Pharmaceuticals Limited to enhance its tumor intervention and radionuclide-drug conjugate R&D platforms.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grand Pharmaceutical Group Ltd. published the original content used to generate this news brief on May 18, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎国际,美股交易,港股交易,交易美股,股票信息,股价,美股行情,美股打新,港股打新,IPO打新,购买美股,全球投资","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2536656109"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2536656109\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2536656109?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-18 18:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2536656109","market":"nz","top_or_hot":-1,"title":"Grand Pharmaceutical Group Ltd. Obtains Class A \"Radiation Safety License\" for Nuclear Medicine R&D Base, Operations to Start in June","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Grand Pharmaceutical Group Ltd. Obtains Class A \"Radiation Safety License\" for Nuclear Medicine R&amp;D Base, Operations to Start in June\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Grand Pharmaceutical Group Limited has announced that its nuclear medicine R&amp;D and production base in Wenjiang District, Chengdu, has secured a Class A \"Radiation Safety License\" from the Ministry of Ecology and Environment of China. This significant regulatory approval will allow the facility to commence operations in June. The base, which began construction in late 2022, has achieved rapid development milestones, breaking industry construction records. This facility is integral to Grand Pharmaceutical's strategic expansion in the fields of R&amp;D, production, and sales of advanced anti-tumor technologies. The Group collaborates with organizations such as Sirtex Medical Pty Limited and Telix Pharmaceuticals Limited to enhance its tumor intervention and radionuclide-drug conjugate R&amp;D platforms.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grand Pharmaceutical Group Ltd. published the original content used to generate this news brief on May 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Grand Pharmaceutical Group Ltd. Obtains Class A \"Radiation Safety License\" for Nuclear Medicine R&D Base, Operations to Start in June</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGrand Pharmaceutical Group Ltd. Obtains Class A \"Radiation Safety License\" for Nuclear Medicine R&D Base, Operations to Start in June\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-18 18:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Grand Pharmaceutical Group Ltd. Obtains Class A \"Radiation Safety License\" for Nuclear Medicine R&amp;D Base, Operations to Start in June\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Grand Pharmaceutical Group Limited has announced that its nuclear medicine R&amp;D and production base in Wenjiang District, Chengdu, has secured a Class A \"Radiation Safety License\" from the Ministry of Ecology and Environment of China. This significant regulatory approval will allow the facility to commence operations in June. The base, which began construction in late 2022, has achieved rapid development milestones, breaking industry construction records. This facility is integral to Grand Pharmaceutical's strategic expansion in the fields of R&amp;D, production, and sales of advanced anti-tumor technologies. The Group collaborates with organizations such as Sirtex Medical Pty Limited and Telix Pharmaceuticals Limited to enhance its tumor intervention and radionuclide-drug conjugate R&amp;D platforms.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grand Pharmaceutical Group Ltd. published the original content used to generate this news brief on May 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TLX.AU","symbol_name":"TELIX PHARMACEUTICALS LTD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250518:nNDL6DW2Yw:1","article_id":"2536656109","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2536656109","pubTimestamp":1747564292,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Grand Pharmaceutical Group Ltd. Obtains Class A \"Radiation Safety License\" for Nuclear Medicine R&D Base, Operations to Start in June. Grand Pharmaceutical Group Limited has announced that its nuclear medicine R&D and production base in Wenjiang District, Chengdu, has secured a Class A \"Radiation Safety License\" from the Ministry of Ecology and Environment of China. This significant regulatory approval will allow the facility to commence operations in June. The base, which began construction in late 2022, has achieved rapid development milestones, breaking industry construction records. This facility is integral to Grand Pharmaceutical's strategic expansion in the fields of R&D, production, and sales of advanced anti-tumor technologies. The Group collaborates with organizations such as Sirtex Medical Pty Limited and Telix Pharmaceuticals Limited to enhance its tumor intervention and radionuclide-drug conjugate R&D platforms.Disclaimer: This news brief was created by Public Technologies","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TLX.AU":"TELIX PHARMACEUTICALS LTD","BK1191":"制药","00512":"远大医药","BK7067":"生物科技"},"translate_title":"远大医药集团核医学研发基地获得A类“辐射安全许可证”6月开始运营","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TLX.AU":0.9,"00512":0.9},"content_text":"Grand Pharmaceutical Group Ltd. Obtains Class A \"Radiation Safety License\" for Nuclear Medicine R&D Base, Operations to Start in June\n    \n\n        Grand Pharmaceutical Group Limited has announced that its nuclear medicine R&D and production base in Wenjiang District, Chengdu, has secured a Class A \"Radiation Safety License\" from the Ministry of Ecology and Environment of China. This significant regulatory approval will allow the facility to commence operations in June. The base, which began construction in late 2022, has achieved rapid development milestones, breaking industry construction records. This facility is integral to Grand Pharmaceutical's strategic expansion in the fields of R&D, production, and sales of advanced anti-tumor technologies. The Group collaborates with organizations such as Sirtex Medical Pty Limited and Telix Pharmaceuticals Limited to enhance its tumor intervention and radionuclide-drug conjugate R&D platforms.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grand Pharmaceutical Group Ltd. published the original content used to generate this news brief on May 18, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}